Fig. 6: scRNA-seq analysis of Meta4 cells treated with either DMSO or Selumetinib.

a UMAP of DMSO-treated and Selumetinib-treated Meta4 samples with sample overlay (left) and subpopulation-matched cluster overlay (right). b PANTHER gene ontology classification results from DMSO vehicle-treated and Selumetinib-treated Meta4 samples. Top 300 differentially expressed genes in either DMSO vehicle-treated or Selumetinib-treated Meta4 samples were used for the analysis. c Heatmap of upregulated genes in DMSO vehicle-treated or Selumetinib-treated samples. Upregulated genes were defined as those expressed in at least 50% of the cells in the sample with at least 0.75 log fold-change over the other sample. P-values were calculated using a two-tailed Wilcoxon Rank Sum test with Bonferroni correction and were <1e⁻⁴⁰. Rows correspond to individual genes and columns are individual cells, arranged by sample and subpopulation. Yellow corresponds to high expression, black corresponds to neither high nor low expression, and purple corresponds to low expression. d Dot plots showing selected markers for cancer and gastric cancer (left), as well as markers for gastric cancer stem cells (GCSCs), SPEM, IM, proliferation, and normal gastric epithelium (right). Results are shown for matched subpopulations (1–4) and split by treatment (DMSO vehicle or Selumetinib). The dot size represents the percent of cells within the matched subpopulation with detected expression of the gene and color intensity reflects the average expression in those cells with detectable gene expression.